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Background: Photodynamic therapy (PDT) of solid cancers comprises the administration of a photosensitizer followed
by illumination of the photosensitizer-replete tumor with laser light. This induces a state of local oxidative stress,
culminating in the destruction of tumor tissue and microvasculature and induction of an anti-tumor immune
response. However, some tumor types, including perihilar cholangiocarcinoma, are relatively refractory to PDT,
which may be attributable to the activation of survival pathways in tumor cells following PDT (i.e., activator protein 1
(AP-1)-, nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB)-, hypoxia-inducible factor 1-alpha
(HIF-1α)-, nuclear factor (erythroid-derived 2)-like 2 (NFE2L2)-, and unfolded protein response-mediated pathways).
Methods: To assess the activation of survival pathways after PDT, human perihilar cholangiocarcinoma (SK-ChA-1) cells
were subjected to PDT with zinc phthalocyanine (ZnPC)-encapsulating liposomes. Following 30-minute incubation
with liposomes, the cells were either left untreated or treated at low (50 mW) or high (500 mW) laser power (cumulative
light dose of 15 J/cm2). Cells were harvested 90 min post-PDT and whole genome expression analysis was performed
using Illumina HumanHT-12 v4 expression beadchips. The data were interpreted in the context of the survival pathways.
In addition, the safety of ZnPC-encapsulating liposomes was tested both in vitro and in vivo.
Results: PDT-treated SK-ChA-1 cells exhibited activation of the hypoxia-induced stress response via HIF-1α and
initiation of the pro-inflammatory response via NF-кB. PDT at low laser power in particular caused extensive
survival signaling, as evidenced by the significant upregulation of HIF-1- (P < 0.001) and NF-кB-related (P < 0.001)
genes. Low-power PDT was less lethal to SK-ChA-1 cells 90 min post-PDT, confirmed by annexin V/propidium
iodide staining. In vitro toxicogenomics and toxicological testing in chicken embryos and mice revealed that the
ZnPC-encapsulating liposomes are non-toxic.
Conclusions: PDT-treated perihilar cholangiocarcinoma cells exhibit extensive survival signaling that may
translate to a suboptimal therapeutic response and possibly tumor recurrence. These findings encourage the
development of photosensitizer delivery systems with co-encapsulated inhibitors of survival pathways.
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Photodynamic therapy (PDT) is a non-to-minimally inva-
sive treatment modality that is used for the curative or pal-
liative treatment of early-stage and late-stage solid cancers,
respectively. The therapy relies on the accumulation of a
non-toxic photosensitizer in the tumor following topical or
systemic administration. Subsequently, the tumor is light-
irradiated locally at a wavelength that corresponds to the
red absorption peak of the photosensitizer. This leads to
photosensitizer activation and generation of cytotoxic re-
active oxygen species (ROS) via type I (superoxide anion)
and/or type II (singlet oxygen) photochemical reactions.
Extensive intratumoral ROS production initiates several
key processes that culminate in the removal of the tumor,
including: (1) induction of different forms of tumor cell
death, (2) destruction of tumor microvasculature, (3) blood
flow stasis and consequent tumor hypoxia/anoxia, and (4)
induction of an anti-tumor immune response (reviewed in
[1–3]).
Although PDT is highly effective in some cancer types
(e.g., basal cell carcinoma, early-stage esophageal carcin-
oma) [4–7], other solid cancers are relatively unresponsive
to PDT (e.g., nasopharyngeal carcinoma [8], perihilar chol-
angiocarcinoma [9]). This therapeutic recalcitrance may be
explained by three key factors. First, the route of photosen-
sitizer administration may be suboptimal for a specific
tumor type, thereby deterring optimal photosensitizer
accumulation in the tumor. Second, the approved
first-generation photosensitizers (i.e., hematoporphy-
rin derivatives and 5-aminolevulinic acid) exhibit poor
photophysical and physicochemical properties, leading
to insufficient and/or heterogeneous ROS productionFig. 1 Induction of survival signaling after PDT. PDT-mediated ROS produc
activator protein 1 (AP-1), (2) the unfolded protein response in reaction to
nuclear factor (erythroid-derived 2)-like 2 (NFE2L2), (4) the inflammatory res
enhancer in B-cells (NF-кB), and (5) the hypoxia-induced stress response via
from [10]throughout the tumor bulk. Third, activation of sur-
vival pathways by tumor cells as a result of PDT may lead
to insufficient tumor cell death following PDT [10].
To resolve these issues, a novel PDT modality was
proposed based on the encapsulation of the photosensi-
tizer zinc phthalocyanine (ZnPC) into polyethylene gly-
col (PEG)-coated liposomes [11]. Accordingly, three
distinct ZnPC-containing nanoparticulate formulations
were developed that are either targeted to tumor cells
(tumor cell-targeting liposomes), tumor endothelium
(endothelium-targeting liposomes), or tumor intersti-
tium (interstitially-targeted liposomes (ITLs)) [11]. This
comprehensive tumor-targeting strategy is expected to
augment therapeutic efficacy and minimize photosensi-
tivity and phototoxicity that are observed in patients
treated with currently approved PDT modalities.
The aims of this study were to evaluate whether ZnPC-
encapsulating ITLs (ZnPC-ITLs) are safe for future clinical
application using toxicogenomics [12], chicken embryos,
and mice as toxicological test models and to study the
PDT-induced activation of survival pathways in human
perihilar cholangiocarcinoma cells – i.e., cells derived from
a cancer that is recalcitrant to PDT. For the latter aim,
whole genome gene expression profiles were determined
in the early phase (90 min) after PDT in accordance with
literature [13] and the data were analyzed in the context of
the five major PDT-induced survival pathways [10] (Fig. 1).
The main findings were, first, that ZnPC-ITLs are not
toxic in vitro and in vivo up to a 500-μM and 2.5-mM final
lipid concentration, respectively, at a ZnPC:lipid molar ra-
tio of 0.003. Second, irradiation of cells at low laser power
(50 mW, 15 J/cm2) caused considerable survival signalingtion results in activation of (1) the immediate early gene response via
endoplasmic reticulum (ER) stress, (3) the antioxidant response via
ponse via activation of nuclear factor of kappa light polypeptide gene
hypoxia-inducible factor 1-alpha (HIF-1α). Data and figure adapted
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(HIF-1) and nuclear factor of kappa light polypeptide gene
enhancer in B-cells (NF-кB), which was associated with
limited photokilling capacity. Irradiation of cells at high
laser power (500 mW, 15 J/cm2) was associated with less
extensive survival signaling and resulted in more profound
cell death.Results
PDT efficacy
The in vitro proof-of-concept regarding ZnPC-ITLs as
part of a novel multi-targeting strategy for PDT was pro-
vided previously [14]. However, this study did not exam-
ine the effect of laser power on post-PDT viability. It
was hypothesized that low laser power (i.e., low degree
of ROS production per unit time) would allow cells to
cope with ROS-induced damage, whereas high laser
power would be more toxic to cells. To investigate the
influence of laser power on PDT efficacy, SK-ChA-1
cells were incubated with ZnPC-ITLs and either not ir-
radiated (dark toxicity, designated as ‘ITL’) or irradiated
at high laser power (500 mW, designated as ‘ITL 500’)
or low laser power (50 mW, designated as ‘ITL 50’) with
a cumulative radiant exposure of 15 J/cm2. As shown in
Fig. 2a, cells in the ITL group exhibited slightly higherFig. 2 Viability of SK-ChA-1 cells after ZnPC-ITL-PDT. SK-ChA-1 cells were in
the dark (ITL) or were irradiated with 50-mW (ITL 50) or 500-mW (ITL 500) l
activity and the extent of cell death were assessed after 24 hours with a W
control cells that were set at 100 %. Alternatively, the mode of cell death w
For this purpose, cells were stained with Alexa Fluor 488-conjugated annex
(PI-positive), apoptotic cells are shown in green (PI-negative, annexin V-positive)
Values are presented as mean + SD for n = 6 per group. Readers are referred tmetabolic activity than the control cells 24 h after treat-
ment, whereas metabolic activity was completely abro-
gated in the treated cells. Cell death was assessed with
the SRB protein assay, which revealed that cell viability
had decreased to 47.6 % and 51.4 % (normalized to the
control group) in the ITL 50 and ITL 500 groups, re-
spectively (Fig. 2b).
In addition, SK-ChA-1 cells were stained with annexin
V and PI 90 min (Fig. 2c) and 24 h (Fig. 2d) after PDT to
evaluate the mode of cell death by flow cytometry. After
90 min, the ITL group paralleled the control group with a
cell viability of approximately 90 %, whereas 43.6 % and
27.2 % of cells were viable in the ITL 50 and ITL 500
groups, respectively (Fig. 2c). The difference in cell viabil-
ity between the treatment groups was abolished 24 h after
PDT (Fig. 2d), suggesting that execution of cell death pro-
grams had not yet completed 90 min after low light dose
PDT and that laser power therefore dictates the rate at
which cell death programs are executed.
In vitro and in vivo toxicity
Next to efficacy, the safety of a new liposomal formulation
is a critical parameter in the preclinical development tra-
jectory. Therefore, in vivo toxicity was evaluated in two
different animal models, namely in chicken embryos and
in C57BL/6 mice. The chicken embryo model was chosencubated with 500 μM ZnPC-ITLs (final lipid concentration) and kept in
aser light at a cumulative radiant exposure of 15 J/cm2. Metabolic
ST-1 assay (a) and SRB assay (b), respectively. Data were normalized to
as assessed 90 minutes (c) or 24 hours (d) post-PDT by flow cytometry.
in V and propidium iodide (PI). Necrotic cells are represented in red
, and healthy cells are represented in white (PI-negative, annexin V-negative).
o section Statistical analysis for the significance of the statistical symbols
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tute for mammalian models [15]. Alternatively, a mouse
model was used to study long-term toxicity. As shown in
Additional file 1: Figure S1, systemically administered
ZnPC-ITLs did not exhibit any toxicity. In addition, whole
genome microarray-based toxicogenomics is considered a
valuable tool for evaluating the toxicity of xenobiotics [12,
16]. Therefore, as a complementary method to the in vivo
toxicity testing, the in vitro toxicity of ZnPC-ITLs was ana-
lyzed in SK-ChA-1 cells by microarray analysis. SK-ChA-1
control cells and cells that were incubated with ZnPC-
ITLs in the dark (ITL) exhibited similar transcriptional re-
sponses (Fig. 3a). None of the genes were differentially
expressed when comparing the ITL group to the control
group, corroborating the in vivo data at a molecular level.Gross transcriptional response to PDT
In addition to the toxicogenomic profile of ZnPC-ITLs,
the transcriptomic data was used to gain insight in the
immediate early gene response [13] and explain the dif-
ferences in cell viability that were observed 90 min
post-PDT (Fig. 2c). As depicted in Fig. 3a, the global
molecular response of the ITL 50 and ITL 500 groups
were not associated and both groups showed a distinct
response relative to the control group. The ITL 500
modality resulted in the upregulation of 213 genes and
downregulation of 375 genes (588 total) compared to
the control regimen (Fig. 3b). The number of differen-
tially expressed genes in the ITL 50 group relative to
control was ~10-fold greater (i.e., 5,598) versus the ITL
500 group. Cells in the ITL 50 and the ITL 500 group ex-
hibited some overlap in differentially expressed genes,
namely 154 upregulated genes and 218 downregulated
genes.Fig. 3 a Principal component analysis of SK-ChA-1 cells that were either untrea
and kept in the dark (ITL, in green), or treated with 500-mW (ITL 500, in orange)
component (PC) accounts for the variability in the data is indicated in parenthe
and downregulated genes per group (in-circle values) and the number of overl
overlapping region) between the various treatment groups compared to the co
per group comprises the sum of all regions in a given circleDifferential gene regulation in response to PDT
To gain insight in the key processes that are initiated by
PDT at the molecular level, the top increased and de-
creased genes were ranked based on the log2 fold-change
(Fig. 4, with more detailed information in Tables 1 and 2).
Compared to the control group, the ITL 50 group exhib-
ited more profound changes in gene expression than the
ITL 500 group. Of note, the microarray expression data
were validated by determining the transcript levels of spe-
cific genes by qRT-PCR, which revealed a strong correl-
ation (Additional file 2: Figure S2).
As shown in Table 1, the top upregulated genes in the
ITL 50 group are involved in chemotaxis (chemokine (C-X-
C motif) ligand 1 (CXCL1) and CXCL2), inflammation
(interleukin 8 (IL8), FBJ murine osteosarcoma viral onco-
gene homolog (FOS)), and the immune response (colony
stimulating factor 2 (CSF2)), whereas downregulated genes
are associated with cell adhesion (thrombospondin 1
(THBS1)) and the extracellular matrix (matrix metallo-
peptidase 1 (MMP1), MMP10). In contrast, treatment
of SK-ChA-1 cells at 500-mW laser power activated tran-
scripts related to mitogen-activated protein (MAP) kinase
(MAPK) signaling (dual specificity phosphatase 6
(DUSP6)), the stress response (activating transcription fac-
tor 3 (ATF3)), and response to ROS and unfolded proteins
(FOS, heat shock 70 kDa protein 1A (HSPA1A)) (Table 2).
High-power irradiation also resulted in downregulation of
genes involved in cell cycle arrest (cyclin-dependent kinase
inhibitor 1B (CDKN1B)) and apoptosis initiation (Bcl2
modifying factor (BMF)).
In addition, gene ontology analysis was performed using
the DAVID Bioinformatics Resources 6.7 database to gain
insight in the upregulated genes (absolute log2 fold-change
of > 1, corrected P-value of < 0.05 (section Data analysis
and processing)) in the ITL 50 and ITL 500 group in termsted (in red), incubated with 500 μM ZnPC-ITLs (final lipid concentration)
or 50-mW (ITL 50, in purple) laser light. The extent to which a principal
ses. b Venn diagram showing the number of non-overlapping upregulated
apping upregulated and downregulated genes (values in the respective
ntrol group. The total number of genes that were up- and downregulated
Fig. 4 Top upregulated and downregulated PDT-induced genes as expressed by the log2 fold-change in gene expression in the ITL 50 (a) and
ITL 500 group (b) compared to the control group. Genes were ordered by decreasing absolute log2 fold-change. Values are presented as the
mean of n = 3 per group
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(GO) terms were evaluated and are presented in Table 3.
Characterization of the top 8 overrepresented GO terms
revealed that the GO term “response to stress” applied to
both the ITL 50 (involving 92 genes) and the ITL 500 (in-
volving 16 genes) group. In the ITL 50 group, genes anno-
tated with the GO terms “response to biotic stimulus” and
“apoptosis” were overrepresented, as reflected by a P-value
of 1.2 × 10−17 and 2.0 × 10−7, respectively. In contrast, the
GO terms “MAP kinase phosphatase” and “regulation ofTable 1 Top 10 most up- and downregulated genes induced by th
Gene: Full name:
CXCL1 chemokine (C-X-C motif) ligand 1
IL8 interleukin 8
C15orf48 chromosome 15 open reading frame 48
CXCL2 chemokine (C-X-C motif) ligand 2
UBD ubiquitin D
CSF2 colony stimulating factor 2
CCL20 chemokine (C-C motif) ligand 20
PDZK1IP1 PDZK1 interacting protein 1
CCL2 chemokine (C-C motif) ligand 2
FOS FBJ murine osteosarcoma viral oncogene homolog
LOC651309
THBS1 thrombospondin 1
SOX21 SRY (sex determining region Y)-box 21
TOX3 TOX high mobility group box family member 3
CBLN1 cerebellin 1 precursor
CGNL1 cingulin-like 1
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1
SPOCK1 testican 1
MMP10 matrix metallopeptidase 10
MMP1 matrix metallopeptidase 1
Gene functions were obtained from The Gene Ontology Consortium (http://www.gecellular process” were overrepresented in the ITL 500
group. In summary, the main processes that were initiated
following PDT include oxidative stress, cell death, and
inflammation.Activation of survival pathways following PDT
Based on the survival pathways depicted in Fig. 1 and
described in [10], survival signaling pathways were con-
structed in PathVisio to investigate whether and to whate 50-mW PDT regimen
Function:
Cell proliferation, chemotaxis, inflammation
Angiogenesis, chemotaxis, inflammation
Chemotaxis, inflammation
Protein ubiquitination, aggresome formation, myeloid DC differentiation
Macrophage activation, DC differentiation, immune response
Chemotaxis, inflammation
Chemotaxis, inflammation
Inflammation, cellular response to ROS, DNA methylation
Cell adhesion, extracellular matrix organization
Transcription from RNA polymerase II promoter, SC differentiation
DNA-dependent transcription
Positive regulation of synapse assembly
Motor activity
Xenobiotic metabolic processes, drug metabolic processes
Neuron migration, neurogenesis
Proteolysis, extracellular matrix disassembly
Proteolysis, extracellular matrix disassembly
neontology.org/)
Table 2 Top 10 most up- and downregulated genes induced by the 500-mW PDT regimen
Gene: Full name: Function:
FOS FBJ murine osteosarcoma viral oncogene
homolog
Inflammation, cellular response to ROS, DNA methylation
DUSP6 dual specificity phosphatase 6 Inactivation of MAPK activity
KREMEN2 kringle containing transmembrane
protein 2
Wnt receptor signaling pathway
ATF3 activating transcription factor 3 Response to stress
HSPA1A heat shock 70 kDa protein 1A Response to unfolded protein, ubiquitin protein ligase binding
IL8 interleukin 8 Angiogenesis, chemotaxis, inflammation
RHOB ras homolog family member B GTP binding, apoptotic process, cellular response to H2O2
SNORD38A small nucleolar RNA, C/D box 38A
FOSB FBJ murine osteosarcoma viral oncogene homolog B Transcription factor binding
CXCL1 chemokine (C-X-C motif) ligand 1 Cell proliferation, chemotaxis, inflammation
SOX21 SRY (sex determining region Y)-box 21 Transcription from RNA polymerase II promoter, stem cell differentiation
CHAC1 ChaC, cation transport regulator homolog 1 Intrinsic apoptotic signaling pathway in response to ER stress, negative
regulator of Notch signaling pathway
CDKN1B cyclin-dependent kinase inhibitor 1B Cell cycle arrest
NEDD9 neural precursor cell expressed, developmentally
down-regulated 9
Cell adhesion, cell division, cytoskeleton organization
AY358241
STC2 stanniocalcin 2 Cellular calcium ion homeostasis
FBXO32 F-box protein 32 Protein ubiquitination, response to denervation involved in regulation of
muscle adaptation
EFNA1 ephrin-A1 Activation of MAPK activity, cell migration, aortic valve morphogenesis
BMF Bcl2 modifying factor Positive regulation of intrinsic apoptotic signaling pathway
DDIT4 DNA-damage-inducible transcript 4 Response to hypoxia, intrinsic apoptotic signaling pathway in response to DNA
damage by p53 class mediator, negative regulation of TOR signaling cascade
Gene functions were obtained from The Gene Ontology Consortium (http://www.geneontology.org/)
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SK-ChA-1 cells (Figs. 5 and 6).Activation of ASK-1 and consequent JNK and p38 MAPK
signaling
Apoptosis signal regulating kinase 1 (ASK-1) can be acti-
vated in two distinct ways: (1) as a result of ROS produc-
tion and (2) via tumor necrosis factor (TNF) production
and subsequent tumor necrosis factor receptor-associated
factor 2 (TRAF2), TRAF5, and TRAF6 signaling, all of
which associate with ASK-1 and stimulate autophosphoryl-
ation and activation of ASK1 [17]. As depicted in Fig. 5a,
activator protein 1 (AP-1, consisting of JUN and FOS,
amongst others) was upregulated in both the ITL 50
and ITL 500 groups. Relative to the control group, nu-
merous downstream genes of AP-1 signaling that exert
pro-inflammatory and proliferative functions were more
highly expressed in the ITL 50 group, including TNF, cyc-
lin D1 (CCND1), heparin-binding EGF-like growth factor
(HBEGF), B-cell CLL/lymphoma 3 (BCL3), and jun B
proto-oncogene (JUNB) compared to the ITL 500 group.NFE2L2 signaling following PDT
Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a
transcription factor that is ubiquitously expressed in the
cytoplasm and degraded via kelch-like ECH-associated pro-
tein 1 (KEAP1) under non-stressed conditions. During oxi-
dative stress the redox-sensitive KEAP1 is oxidized, causing
dissociation of KEAP1 from NFE2L2 [18]. In turn, NFE2L2
dimerizes with small Maf, JUN, and FOS proteins, which
then translocate to the nucleus to bind to the antioxidant
responsive element (ARE) [19, 20]. This binding initiates
transcription of a plethora of antioxidant-responsive genes.
An overview of the effects of ZnPC-ITL-PDT treatment on
the NFE2L2-mediated pathway is shown in Fig. 5b. PDT re-
sulted in modest downregulation of NFE2L2 transcription
levels, although cells in both the ITL 50 and ITL 500
groups upregulated NFE2L2 binding partners (JUN, JUNB,
FOS). Despite the fact that NFE2L2 was downregulated in
the ITL 500 group, several NFE2L2 target genes were up-
regulated (e.g., heme oxygenase 1 (HMOX1), NAD(P)H de-
hydrogenase, quinone 2 (NQO2), sulfiredoxin 1 (SRXN1)).
Furthermore, expression of various genes involved in
glutathione and redox cycling (glutamate-cysteine
Table 3 Overrepresented GO terms in the ITL 50 and ITL 500
group
ITL 50
Cluster [ES] GO term Count P-value (FDR)
1 [12.96] Response to biotic stimulus 45 1.2E-17
2 [11.83] Response to stress 92 6.2E-13
3 [5.89] Apoptosis 39 2.0E-7
4 [5.77] Response to cytokine stimulus 14 9.8E-8
5 [5.13] Regulation of apoptosis 47 2.4E-7
6 [4.92] Regulation of response to stress 25 1.3E-7
7 [4.38] Chemotaxis 19 1.3E-7
8 [4.18] bZIP transcription factor 10 5.7E-6
ITL 500
Cluster [ES] GO term Count P-value
1 [3.97] Response to stress 16 2.4E-5
2 [3.55] MAP kinase phosphatase 4 1.8E-6
3 [3.15] Regulation of cellular process 32 7.2E-5
4 [2.68] Response to chemical stimulus 12 6.1E-4
5 [2.41] Angiogenesis 6 5.7E-5
6 [2.33] Fos transforming protein 4 8.5E-7
7 [2.08] Regulation of cell proliferation 8 6.1E-3
8 [1.89] Regulation of catalytic activity 9 2.2E-3
Gene ontology (GO) analysis was performed using the DAVID Bioinformatics
Resources 6.7 database (https://david.ncifcrf.gov/). Significantly upregulated
genes were loaded into DAVID and the HumanHT-12_V3_0_R2_11283641_A was
selected as a background reference. An EASE score of 0.1 was used in the analysis
and FDR-corrected P-values are presented
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ase, modifier subunit (GCLM), glutathione reductase
(GSR)) were decreased in the ITL 50 group. Overall,
there was no unequivocal induction of NFE2L2-related
antioxidant-responsive genes 90 min after PDT in either
group (Table 4).
Unfolded protein response following PDT
The unfolded protein response (UPR) is a process that is
initiated upon ER stress. In response to the accumulation
of unfolded and misfolded proteins in the ER, protein
translation is stalled, unfolded and misfolded proteins are
degraded, and molecular players involved in protein fold-
ing are upregulated (reviewed in [21]). However, apoptotic
cell death is triggered when the amount of unfolded and
misfolded proteins exceeds a certain threshold [21, 22].
During UPR signaling, HSPA5 binds unfolded and mis-
folded proteins in the ER lumen, which causes activation
of endoplasmic reticulum to nucleus signaling 1 (ERN1),
eukaryotic translation initiation factor 2-alpha kinase 3
(EIF2AK3), and ATF6 (Fig. 5c). Activation of these pro-
teins in turn triggers the release of various transcription
factors, which include X-box binding protein 1 (XBP1),
ATF4, and ATF6. As shown in Fig. 5c, both the ITL 50 andITL 500 groups did not clearly induce these transcription
factors. In fact, various downstream genes of XBP1, ATF4,
and ATF6 were downregulated rather than upregulated
(e.g., ER degradation enhancer, mannosidase alpha-like 1
(EDEM1), heat shock protein 90 kDa beta (HSP90B1)) in
both groups 90 min after PDT, altogether attesting to
the disinvolvement of the UPR survival pathway in
ZnPC-ITL-PDT.
Activation of pro-inflammatory signaling via NF-кB
NF-кB consists of a subfamily of proteins that include
NF-кB1, NF-кB2, v-rel avian reticuloendotheliosis viral
oncogene homolog (REL), RELA, and RELB. Activation
of NF-кB following PDT can occur by various pathways
as shown in Fig. 6a. First, NF-кB can be activated via dir-
ect activation of conserved helix-loop-helix ubiquitous
kinase (CHUK) during hypoxic conditions, which inhibits
inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase beta (IKBKB) [23]. Second, NF-кB activation
occurs via inhibition of oxygen-dependent egl-9 family
hypoxia-inducible factor 2 (EGLN2) that leads to CHUK
activation and consequently IKBKB inhibition [23]. Third,
NF-кB can be activated via tumor necrosis factor receptor
superfamily, member 1A (TNFRSF1A) signaling, leading
to TRAF6 activation and NF-кB induction [24]. The acti-
vation of NF-кB promotes various pathways directly and
indirectly related to cell survival, including proliferation,
inflammation, and survival.
As presented in Fig. 6a, treatment of SK-ChA-1 cells at
low laser power resulted in upregulation of all members of
the NF-кB subfamily. Strikingly, this response was not ob-
served in the ITL 500 group, suggesting that the acute
damage induced by the high-dose irradiation favored cell
death signaling rather than cell salvage signaling. Further-
more, the ITL 50 group exhibited upregulated expression
of NF-кB downstream genes (Table 4), including CSF2,
CXCL2, and vascular cell adhesion molecule (VCAM). In
addition, cells in the ITL 50 group also upregulated vari-
ous pro-inflammatory cytokines, including IL1 alpha
(IL1A), IL1 beta (IL1B), and IL8, with a log2 fold-change
of 0.93, 1.48, and 6.75, respectively.
Activation of HIF-1 following PDT
Under normoxic conditions, HIF1A is hydroxylated by
EGLN1 and hypoxia inducible factor 1, alpha subunit in-
hibitor (HIF1AN), which mediates recognition of HIF1A
by von Hippel-Lindau tumor suppressor, E3 ubiquitin
protein ligase (VHL) that targets HIF1A for ubiquitin-
mediated proteasomal degradation. However, during oxi-
dative stress and hypoxia, the oxygen sensors EGLN1 and
HIF1AN are inhibited and thereby prevent degradation of
HIF1A (reviewed in [25]). Downstream HIF-1 target genes
then promote glycolysis, angiogenesis, and proliferation,
all of which support cell survival. As shown in Fig. 6b,
Fig. 5 (See legend on next page.)
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Fig. 5 PDT-induced survival signaling. Genes are mapped that are involved in MAP3K5 (also known as ASK-1) signaling (a), NFE2L2 signaling (b),
and the unfolded protein response following PDT (c). The color and intensity of the box indicates the direction and extent of the log2 fold-change for
the indicated gene, respectively (lower right corner of each panel). Grey boxes signify probes that exhibited poor quality or were not included in the
gene expression analysis. Each gene box, which typically comprises multiple probes as indicated by vertical splits, is horizontally divided in two halves
corresponding to the PDT regimens (legend lower left). All comparisons were made between the PDT-treated groups versus the control group.
Dashed lines indicate interactions that are not directly transcriptionally regulated. The molecular pathways were adapted from [10]
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90 min post-PDT in the ITL 50 group (Table 4). ZnPC-
ITL-PDT led to upregulation of endothelin 1 (EDN1), a
gene that is downstream of HIF1A and a known vasocon-
strictor, in both groups after PDT. Unexpectedly, down-
regulation of vascular endothelial growth factor A
(VEGFA), solute carrier family 2 (facilitated glucose trans-
porter), member 1 (SLC2A1), and insulin-like growth fac-
tor binding protein 1 (IGFBP1) was observed in both
groups.
Discussion
Perihilar cholangiocarcinoma is a rare but highly lethal
cancer that is typically diagnosed at an advanced tumor
stage, accounting for the fact that the tumor cannot be
resected in approximately 70–80 % of the patients [26]. It
was demonstrated in a cohort of non-resectable patients
that, when standard intervention (stenting) was combined
with PDT, the median survival could be prolonged from 6
to 9 months to 21 months post-diagnosis (summarized in
[27]). However, the management of non-resectable perihilar
cholangiocarcinoma remains palliative. Inasmuch as PDT is
a promising treatment strategy for perihilar cholangiocarci-
noma, novel routes have been explored to increase thera-
peutic efficacy and to develop a more patient-friendly PDT
strategy [11]. For those purposes, ZnPC-encapsulating lipo-
somes (ITLs), which are part of a novel multi-targeted lipo-
somal delivery platform for PDT [11, 14], were evaluated
for toxicity and for the potential use in PDT of perihilar
cholangiocarcinoma. The experiments demonstrated that
(1) ZnPC-ITLs are not toxic in vitro and in vivo at high
lipid concentrations, (2) irradiation of SK-ChA-1 cells at
high laser power (500 mW, 15 J/cm2) resulted in more pro-
found acute cell death than PDT at low laser power
(50 mW, 15 J/cm2), and (3) irradiation of SK-ChA-1 cells at
low laser power caused considerable survival signaling after
PDT via activation of mainly HIF-1 and NF-кB.
The response of SK-ChA-1 cells to PDT at low (50 mW)
or high laser power (500 mW) was compared. Since PDT
treatment at low laser power causes moderate ROS pro-
duction over an extended period of time [14], cells likely
had the opportunity to activate an antioxidant (possibly
via NFE2L2) and survival response to remediate the acute
effects of ROS and cope with the ROS-induced damage
more effectively than cells that were severely damaged by
the 500-mW laser irradiation. This postulation issupported by the viability data, which demonstrated that
cells irradiated at 50 mW were more viable at 90 min
post-PDT than cells irradiated at 500 mW. The difference
in cell viability at 90 min post-PDT was, however, abol-
ished 24 h after PDT. A possible explanation is that, when
cells are unable to cope with the PDT-inflicted damage,
the execution of cell death programs via either apoptosis,
(programmed) necrosis, and/or autophagy is ultimately
completed. The time required to complete the activated
cell death programs is apparently longer for moderately
damaged cells than for highly damaged cells. Both PDT
regimens also entirely abrogated metabolic activity 24 h
post-PDT, which may be explained by the intracellular
localization of ZnPC. ZnPC is largely confined to mito-
chondria upon cell entry [11], which is the source of elec-
trons for the WST-1-based metabolic activity assay [28].
PDT-induced mitochondrial damage debilitates electron
production and leakage from the electron transport chain,
thereby hampering the reduction of WST-1 to the forma-
zan chromophore. Metabolic perturbations (measured by
WST-1) occur chronologically before cell death-mediated
fragmentation and detachment from the wells plate (mea-
sured by the SRB assay), as a result of which the WST-1
data reflects more profound cell damage than the total
protein assay at 24 h post-PDT.
To understand the molecular events that are triggered
directly after PDT, whole genome expression profiles were
established of PDT-treated SK-ChA-1 cells in the early
phase (90 min) after PDT in line with previous reports [13].
Since the cellular redox state of a cell changes during PDT
as a result of the production of ROS and reactive nitrogen
species (e.g., peroxynitrite) [29], PDT causes activation of a
variety of redox-sensitive proteins and transcription factors
[10]. ASK-1, also known as mitogen-activated protein kin-
ase kinase kinase 5 (MAP3K5)) is associated with thiore-
doxin under physiological conditions and thereby kept
inactive. However, during oxidative stress thioredoxin is
oxidized and dissociates from ASK-1, leading to its activa-
tion [17]. Consequently, JUN N-terminal kinase (JNK, also
designated as MAPK8) and protein 38 (p38) MAPK signal-
ing is induced, leading to the immediate-early gene re-
sponse via AP-1 [30]. Furthermore, UPR signaling and
redox-sensitive transcription factors NFE2L2, NF-кB, and
HIF1A are activated under oxidative stress and are able to
initiate a plethora of processes (reviewed in [10]), including
cell proliferation, inflammation, and angiogenesis.
Fig. 6 (See legend on next page.)
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Fig. 6 PDT-induced survival signaling. Genes are mapped that are involved in NF-кB signaling (a) and HIF-1 signaling (b) following PDT. The color
and intensity of the box indicates the direction and extent of the log2 fold-change for the indicated gene, respectively (lower right corner of each
panel). Grey boxes signify probes that exhibited poor quality or were not included in the gene expression analysis. Each gene box, which typically
comprises multiple probes as indicated by vertical splits, is horizontally divided in two halves corresponding to the PDT regimens (legend lower
left). All comparisons were made between the PDT-treated groups versus the control group. Dashed lines indicate interactions that are not
directly transcriptionally regulated. The molecular pathways were adapted from [10]
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control group, SK-ChA-1 cells subjected to low-power
PDT displayed a different response than cells treated
using high-power PDT. Moreover, the number of up- and
downregulated genes was considerably greater in the ITL
50 group than in the ITL 500 group. These data indicate
that SK-ChA-1 cells treated by low-power PDT attempt to
survive, as evidenced by the significant upregulation of
HIF-1- (P < 0.001) and NF-κB-mediated (P < 0.001) path-
ways. It should be noted, however, that the experiments
were carried out under normoxic conditions. Since HIF-
1A is rapidly degraded under normoxia [31], the effects
that were observed in terms of HIF-1 activation are prob-
ably an underestimation. Nevertheless, in line with the
results of this study, Liu et al. observed significant upregu-
lation of various proinflammatory genes, including FOS,
FOSB, IL8, and tumor necrosis factor, alpha-induced pro-
tein 3 (TNFAIP3) in 5-aminolevulinic acid (5-ALA)-
treated human gingival (Ca9-22) cells [32]. In our study,
SK-ChA-1 cells treated with low-power PDT also demon-
strated extensive upregulation of FOS, FOSB, IL8, and
TNFAIP3 (log2 fold-changes of 4.42, 2.13, 6.75, and 2.75,
respectively). Moreover, Kammerer and co-workers ob-
served significant upregulation of inflammation-related
genes, including CXCL2, CXCL3, IL1A, and IL6 recep-
tor (IL6R)) after non-lethal 5-ALA-PDT in a panel of
prostate and glioblastoma cell lines [33]. Cells in the
ITL 50 group also significantly upregulated CXCL2 and
IL1A, whereas IL6R remained unaffected. Contrary to
expectations, cells in the ITL 50 group downregulated
the NFE2L2-mediated pathway (P < 0.001); an effect
that was absent in the ITL 500 group. This responseTable 4 A ROAST gene set test was performed to evaluate
whether a specific survival pathway was either up- (▲) or
downregulated (▼)
ITL 50 ITL 500
Geneset Genes Direction P-value (FDR) Direction P-value (FDR)
AP-1 18 ▲ 0.102 ▼ 0.927
NFE2L2 13 ▼ <0.001 ▲ 0.927
UPR 22 ▼ 0.141 ▼ 0.164
HIF-1 28 ▲ <0.001 ▼ 0.059
NF-κB 21 ▲ <0.001 ▲ 0.059
The gene sets are based on the specific survival pathways as presented in
Figs. 5 and 6. FDR-corrected P-values are presentedcould be due to the crosstalk between the NF-κB and
NFE2L2 pathways. It has been proposed that RELA, a
subunit of NF-κB, interferes with NFE2L2 activation
through deprivation of CREB binding protein (CREBBP)
and activation of histone deacetylase 3 (HDAC3) [34].
Thus, a strong induction of the NF-κB pathway, as
observed in the ITL 50 group, may impede NFE2L2 sig-
naling. Lastly, the UPR did not seem to be important in
the early phase after PDT in SK-ChA-1 cells, which could
be explained by the localization of ZnPC at the time of
PDT. Since ZnPC translocates from the plasma mem-
brane to intracellular organelles in a time-dependent
manner [35], it is likely that the ZnPC concentration in
the ER is low, as a result of which ER stress and the
UPR were probably less important under these experi-
mental conditions.
The data in this study as well as in previously published
studies plead for the development and use of fourth-
generation photosensitizers (i.e., second-generation photo-
sensitizer encapsulated in a nanoparticulate delivery
system (making it a third-generation photosensitizer) with
co-encapsulated small-molecular inhibitors of survival
pathways) in PDT. In that respect, the HIF-1- and NF-κB-
mediated survival responses that were induced by PDT in
mainly the ITL 50 group comprise potential target sites
for pharmacological intervention. Corroboratively, HIF-1
induction with cobalt chloride in human esophageal car-
cinoma (Het-1a) cells reduced the extent of cell death and
abrogated apoptosis after 5-ALA-PDT [36]. This pro-
survival response was blocked following HIF-1 silencing
with siRNA, which augmented PDT efficacy in the Het-1a
cells [36]. Chen et al. revealed that nanoparticulate delivery
of HIF-1 siRNAs to head-and-neck carcinoma (SSC4) xe-
nografts significantly enhanced photosan-PDT efficacy in
mice [37], leading to 40 % tumor regression within 10 days
post-PDT. Similarly, the combination treatment with
ALA-PDT and celecoxib, an anti-inflammatory drug that
inhibits prostaglandin-endoperoxide synthase 2 (PTGS2) (a
downstream target of HIF-1 and NF-κB), yielded an
additional 40 % reduction in tumor growth compared to
ALA-PDT alone in human cholangiocarcinoma (HuCC-
T1)-bearing mice [38]. Although the authors stated that
increased ROS generation was mainly responsible for the
increased response, it is likely that the inhibition of prosta-
glandin synthesis (reviewed in [39]), which is normally ini-
tiated by PTGS2 to promote survival, also contributed to
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ition of HIF-1α with acriflavine, a small molecule that
prevents the dimerization of HIF-1α with HIF-1β and thus
its activation [40], potentiated PDT efficacy in human
epidermoid carcinoma (A431) cells and SK-ChA-1 cells using
liposomal ZnPC Broekgaarden et al., Inhibition of hypoxia
inducible factor 1 with acriflavine sensitizes tumor cells to
photodynamic therapy with zinc phthalocyanine-encapsulating
cationic liposomes, in preparation [41].
Comparable results were obtained in studies where
other survival pathways were inhibited before PDT.
Coupienne et al. inhibited NF-кB with BAY 11–7082 (an
inhibitor of IKK) prior to 5-ALA-PDT of glioblastoma
cells [42], achieving increased therapeutic efficacy as a
result of an impaired autophagic response, which otherwise
mediates survival. Moreover, verteporfin-PDT induced epi-
dermal growth factor receptor (EGFR) and signal trans-
ducer and activator of transcription 3 (STAT-3) signaling
in ovarian carcinoma (OVCAR-5) and non-small cell lung
cancer (H460) cells [43]. Activation of the STAT-3 pathway
results in the transcription of both HIF-1- and NF-κB tar-
get genes [44, 45]. Accordingly, siRNA-mediated knock-
down of either EGFR or STAT-3 increased PDT efficacy.
At this stage, combination treatments with respect to
PDT and inhibitors in the clinical setting are limited to the
treatment of macular degeneration, in which case VEGF in-
hibitors are employed to deter neovascularization. Never-
theless, the data that have become available to date indicate
that the combined use of PDT and inhibitors of survival
pathways in the form of fourth-generation photosensi-
tizers may be an attractive approach to improve thera-
peutic efficacy.
Conclusions
In summary, ZnPC-encapsulating liposomes are non-toxic
in various in vivo models in the absence of irradiation but
become highly cytotoxic upon PDT in vitro. Low-power
PDT-treated perihilar cholangiocarcinoma cells activate
extensive survival signaling in vitro, which is characterized
by the induction of HIF-1- and NF-кB-related genes.
Induction of these genes concurred with higher viability
90 min after PDT. Such post-PDT survival signaling may
translate to a suboptimal therapeutic response in the clin-
ical setting and possibly tumor recurrence. These findings
encourage the development of photosensitizer delivery
systems with co-encapsulated inhibitors of survival path-




obtained from Avanti Polar Lipids (Alabaster, AL). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene
glycol (DSPE-PEG, average PEG molecular mass of2,000 amu), ZnPC (97 % purity), HEPES (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid), pyridine, and
sulforhodamine B (SRB) were acquired from Sigma-
Aldrich (St. Louis, MO). Acetic acid (glacial), ethidium
bromide, ethylenediaminetetraacetic acid (EDTA), formal-
dehyde solution (36.5–38 % in water), sodium chlor-
ide, and tris(hydroxymethyl)aminomethane (Tris) were
obtained from Merck KGaA (Darmstadt, Germany).
Agarose was purchased from Gibco-BRL (Paisley, UK) and
ethanol was from J.T. Baker (Deventer, the Netherlands).
All lipids were dissolved in chloroform and ZnPC
was dissolved in pyridine at a 178-μM concentration.
All dissolved lipids were stored under a nitrogen at-
mosphere at −20 °C.
Cell culture
Human perihilar cholangiocarcinoma (SK-ChA-1) cells
were maintained at standard culture conditions (37 °C, 5 %
CO2 and 95 % air). SK-ChA-1 cells were cultured in Ros-
well Park Memorial Institute (RPMI) 1640 culture medium
supplemented with 10 % fetal bovine serum (FBS) (v/v)
(Gibco, Invitrogen, Carlsbad, CA), 1 % penicillin/strepto-
mycin (v/v), 1 % L-glutamine (v/v) (both from Lonza,
Walkersville, MD), and 1 × 10−5 % β-mercaptoethanol
(v/v) (Sigma-Aldrich). The cells were passaged weekly
at a 1:10 ratio.
Preparation of ZnPC-ITLs
ZnPC-ITLs were prepared by the lipid film hydration
technique as described previously [14]. Briefly, ZnPC-
ITLs were composed of DPPC and DSPE-PEG (96:4,
molar ratio). ZnPC was incorporated at a ZnPC-to-
phospholipid ratio of 0.003. The liposomes were sized
with a bath sonicator and characterized for size and
polydispersity by photon correlation spectroscopy [14].
Liposome suspensions were purged with nitrogen gas
and stored for a maximum of 3 days at 4 °C in the dark.
PDT protocol
Cells were harvested using Accutase (Innovative Cell
Technologies, San Diego, CA) and seeded in 6-wells cul-
ture plates (Corning Life Sciences, Tewksbury, MA) at a
density of 0.5 × 106 cells/well. After reaching confluence,
cells were washed with PBS and incubated with ZnPC-
ITLs (500 μM final lipid concentration) in serum-free
RPMI 1640 medium (1.5 mL final volume per well) for
30 min at 37 °C in the dark. Control cells received an
equal volume of PBS. In case of PDT, cells were irradi-
ated with a 671-nm diode laser (CNI, Changchun,
China) at a laser power of either 50 or 500 mW until a
cumulative light dose of 15 J/cm2 was reached. PDT was
performed in the dark while the cells were maintained at
37 °C using a hotplate (cat. no. 97042–616, VWR, Rad-
nor, PA).
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Mitochondrial metabolism was assessed using WST-1 re-
agent (Roche). Twenty-four hours post-PDT, the culture
medium was removed and 1,500 μL of WST-1-containing
RPMI medium (at a 1:25 volume ratio, serum- and phenol
red-free) was added to the wells. After 30 min of incuba-
tion under standard culture conditions, 300-μL aliquots
were transferred to 24-wells plates and the absorbance
was read at 450 nm using 600 nm as a reference wave-
length (BioTek Synergy HT multi-well plate reader, Winoo-
ski, VT). Data were normalized to the mean absorbance of
the control cells.
In addition, cell death was determined 24 h post-PDT
using the SRB total protein assay as described by Vichai
et al. [46]. SRB absorbance was read at 564 nm using
690 nm as a reference wavelength (BioTek Synergy HT
multi-well plate reader). Data were normalized to the
mean absorbance of the control cells.
Determination of mode of cell death
The mode of cell death following PDT was analyzed by
flow cytometry using the Alexa Fluor 488 annexin V/
dead cell apoptosis kit (Life Technologies, Carlsbad,
CA). Cells were cultured in 6-wells plates as described
in section "Cell culture" and irradiated as described in
section "PDT protocol". Samples were prepared as de-
scribed previously [14] and assayed on a FACSCanto II
(Becton Dickinson, Franklin Lakes, NJ). Ten thousand
events were recorded in the gated region and data were
analyzed using FlowJo software (Treestar, Ashland, OR).
Healthy cells were defined as annexin V-negative/propi-
dium iodide (PI)-negative, apoptotic cells were defined
as annexin V-positive/PI-negative, and necrotic cells
were defined as PI-positive.
ZnPC-ITL acute toxicity in chicken embryos
Fertilized chicken eggs (White Leghorn) were ordered
from Drost Loosdrecht (Loosdrecht, the Netherlands),
placed on paper towel in an egg incubator (Ova-Easy
190 Advance, Brinsea, Weston-super-Mare, UK), and
maintained under dark conditions at 37.5 °C, 60 % hu-
midity, and a 90° turn interval of 60 min. After 72 h, 2–
3 mL of albumin was removed with a syringe to create
empty volume in the superior portion of the egg. Next,
surgical tape (Transpore White, 3M, St. Paul, MN) was
fastened on the upper part of the eggshell and a small
window (1.5 × 3.0 cm) was cut in the tape-covered egg-
shell that was immediately sealed with a second strip of
surgical tape, after which the egg was placed back in the
incubator. Previously opened eggs were incubated as de-
scribed above but without the turn cycles. On embryonic
development day 12, 50 μL of ZnPC-ITLs (final lipid
concentration of 0.3, 0.5, or 0.7 mM in blood; blood vol-
umes were derived from [47]) in 0.75 % NaCl (i.e., iso-osmolar relative to embryonic blood) or 50 μL of 0.75 %
NaCl (control) was intravenously injected into a large-
sized blood vessel in the chorioallantoic membrane
using a 30-gauge needle and a 1-mL syringe (Becton
Dickinson). All surgical procedures were performed as
fast as possible under sterile conditions in a LAF hood.
Acute toxicity was defined as embryonic death within
24 h after systemic administration.
ZnPC-ITL long term toxicity in mice
The animal experiments were approved by the animal eth-
ics committee of the Academic Medical Center under
BEX103077 and performed in accordance with the NIH
Guide for the Care and Use of Laboratory Animals. Six-to-
eight week old male C57BL/6 mice were purchased from
Charles River (Leiden, the Netherlands). All mice were ac-
climated for 1 week and were provided with water and
standard chow (Harlan Teklad, Harlan, Madison, WI) ad
libitum. Mice were housed under green light at all
times (Philips TL-D 36 W/17, Philips, Eindhoven, the
Netherlands) with standard dark/light cycles to prevent
activation of the photosensitizer. At the start of the ex-
periment, mice were randomly assigned to the ZnPC-
ITL or control group (n = 8 per group). A dose of
2.5 mM ZnPC-ITLs (final lipid concentration in blood,
corresponding to an administered lipid dosage of
200 μmol/kg) was intravenously administered via the
penile vein, whereas control mice received the same
volume of buffer (0.88 % NaCl, 10 mM HEPES, pH = 7.4,
0.292 osmol/kg). Systemic lipid concentration was deter-
mined using a total blood volume of 80 mL/kg [48, 49].
Subsequently, all mice were inspected daily and were
weighed every 4 days as part of toxicological vigilance.
After 28 days, mice were anesthetized and blood was col-
lected via cardiac puncture in heparin- or EDTA-
anticoagulated microtainers (BD, Franklin Lakes, NJ). Bio-
chemical and hematological parameters were determined
by routine clinical chemistry (Department of Clinical
Chemistry, Academic Medical Center). Lung, liver, and
spleen tissue was loafed and fixed in FAA (47.5 % (v/v)
ethanol, 5 % (v/v) acetic acid, 3.7 % (v/v) formaldehyde) at
4 °C, dehydrated in graded concentrations of ethanol and
xylene, embedded in paraffin, cut to 5 μm-thick sections,
and stained with hematoxylin and eosin as described in
[50].
Illumina HumanHT-12 array
SK-ChA-1 cells received either PBS (‘control’) or 500 μM
ZnPC-ITLs (final lipid concentration) and were kept in
the dark (‘ITL’), or were treated with 500-mW (‘ITL 500’)
or 50-mW (‘ITL 50’) laser light (n = 3 per group). Ninety
minutes after PDT, total cellular RNA was extracted from
SK-ChA-1 cells using 1 mL of TRIzol (Life Technologies)
according to the manufacturer’s protocol. RNA samples
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the Netherlands) and eluted in 30 μL RNAse-free H2O.
The quality control, RNA labeling, hybridization, and data
extraction were outsourced to ServiceXS (Leiden, the
Netherlands). The RNA concentration was measured
using a Nanodrop ND-1000 spectrophotometer (Nano-
drop Technologies, Wilmington, DE) and the RNA quality
and integrity was determined using Lab-on-Chip analysis
on the Agilent BioAnalyzer (Agilent Technologies, Santa
Clara, CA). Biotinylated cRNA was prepared using the
Illumina TotalPrep RNA amplification kit (Ambion,
Austin, TX) according to the manufacturer’s specifica-
tions with an input of 200 ng total RNA. Per sample,
750 ng of the obtained biotinylated cRNA samples was
hybridized onto the Illumina HumanHT-12 v4 beadchip
(Illumina, San Diego, CA). Hybridization and washing
were performed according to the Illumina Manual “Dir-
ect Hybridization Assay Guide” and the scanning pro-
cedure was performed on the Illumina iScan (Illumina).
Image analysis and extraction of raw expression data
was performed with Illumina GenomeStudio v2011.1
Gene Expression software with default settings (no
background subtraction and no normalization).
Microarray preprocessing and data analysis
Analyses were carried out with Bioconductor packages
using the statistical software package R (version 3.0.0).
Raw data normalization was performed on the Illumina
sample and control probe profiles by a normexp-by-
control background correction, quantile normalization,
and log2 transformation using the limma package (ver-
sion 3.16.5). The arrayQualityMetrics package (version
3.16.0) was used to confirm that the microarray data
was of good quality. Probes with a detection P-value
of > 0.05 (non-expressed) on all arrays (17,521 of 47,231
probes) were filtered out. Principal component analysis
was performed on unscaled data (function prcomp).
Differential expression between the experimental con-
ditions was assessed with a moderated t-test using the
linear model framework from the limma package.
Resulting P-values were corrected for multiple testing
using the Benjamini-Hochberg false discovery rate.
Corrected P-values of ≤ 0.05 were considered as statisti-
cally significant. Probes were reannotated using the
Bioconductor package IlluminaHumanv4.db package
(version 1.18.0). The microarray data have been depos-
ited in NCBI Gene Expression Omnibus in a MIAME
compliant format and are accessible under GEO series
accession number GSE68292. In addition, a ROAST gene
set test [51] was performed on the selected survival path-
ways (Additional file 3: Table S1) to statistically determine
whether a survival pathway was upregulated or downregu-
lated using 10,000 rotations with Benjamini-Hochberg-
based multiple testing correction. If multiple probes weremapped to the same Entrez Gene identifier according to
the illuminaHumanv4.db package, the probe with the
highest standard deviation was chosen. Survival pathways
were visualized using PathVisio 3.1.3. [52] on the basis of
[10].
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
The experiment as described in section "Illumina
HumanHT-12 array" was repeated, RNA was extracted
(section "Illumina HumanHT-12 array"), and cDNA was
prepared using the oligo-dT-based Transcriptor first
strand cDNA synthesis kit (Roche Diagnostics, Basel,
Switzerland) with an input of 500 ng total RNA. In
addition, 2 μM ribosomal protein S18 (RPS18) reverse tran-
scriptase primer (GCATCGCCGGTCGGCATCG) was
added to each reaction mix. cDNA was synthesized accord-
ing to the manufacturer’s instructions and diluted in
RNAse-free H2O to obtain a final concentration of 5 ng/μL.
For amplification reactions, 5 μL of 2× SensiFAST
SYBR No-ROX master mix (Bioline, London, UK),
1 μL of forward and reverse primer mix (5 μM) (pri-
mer sequences can be found in Additional file 2:
Figure S2), 2 μL of nuclease-free H2O, and 2 μL of
cDNA template (10 ng) were mixed. The qRT-PCR re-
action was carried out using a LightCycler 480 II in-
strument (Roche). The qRT-PCR program consisted of
3 min at 95 °C, 45 cycles of 1 s at 94 °C, 7 s at 65 °C,
and 10 s at 72 °C, followed by melting curve analysis
(65–97 °C, with a temperature increase of 0.11 °C/s).
Subsequently, the quantitative analysis of the qRT-
PCR data was performed according to Ruijter et al.
[53] to calculate the starting concentration (N0) of
each cDNA template. Gene expression levels of the
target genes were normalized to the expression level
of the reference gene RPS18 and log2 fold-changes of
the target genes were calculated based on the mean
values of the control group.
To assure product specificity, all qRT-PCR amplifica-
tion products were separated by gel electrophoresis
using 2 % agarose in 0.5 × TAE buffer (40 mM Tris,
20 mM acetic acid, 1 mM EDTA) in the presence of
0.5 μg/mL ethidium bromide (Additional file 4: Figure
S3). Subsequently, the ethidium bromide-stained qRT-
PCR products were analyzed under UV using an Image-
Quant LAS4000 imager (GE Healthcare Life Sciences,
Piscataway, NJ). The O'GeneRuler DNA Ladder Mix
(#SM1173, Thermo Scientific, Waltham, MA) was used
as a reference to estimate the size of the qRT-PCR
products. In addition, all qRT-PCR products were vali-
dated by sequencing. Therefore, qRT-PCR products
were purified using the QIAquick PCR purification kit
(Qiagen) and sequencing was performed using the
BigDye Terminator Cycle sequencing kit (Thermo
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with an input of 5 ng DNA. Samples were sequenced
on a Lifetech 3130xl genetic analyzer (Applied Biosys-
tems, Waltham, MA) and data analysis was performed
using NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blas-
t.cgi). Sequencing results can be found in Additional
file 5: Table S2.
Statistical analysis
Statistical analysis was performed in GraphPad Prism 5
(GraphPad Software, La Jolla, CA). Normality was tested
with the D’Agostino Pearson omnibus test. Differences
between normally distributed variables were analyzed
with an unpaired t-test or one-way ANOVA with Bon-
ferroni post-hoc test and not normally distributed vari-
ables were analyzed with a Mann–Whitney U test. The
Bonferroni method was applied to adjust the P-value in
case of multiple testing (Additional file 1: Figure S1). In-
tergroup differences groups were indicated with (*) and
differences between the treated groups and the control
group were indicated with (#). A single, double, and triple
sign indicate a P-value of ≤ 0.05, ≤ 0.01, and ≤ 0.001, re-
spectively. Data are presented as mean ± SD throughout
the manuscript.
Additional files
Additional file 1: Figure S1. In vivo toxicity evaluation of ZnPC-ITLs.
(A) Chicken embryos were intravenously injected on embryonic development
day 12 with different concentrations of ZnPC-ITLs (n= 7 per group). The
concentrations indicate the final lipid concentration in blood. Control embryos
were intravenously injected with an equal volume of 0.75 % NaCl.
(B) C57BL/6 mice were intravenously injected with ZnPC-ITLs (2.5 mM,
final lipid concentration in blood, red line) or physiological buffer (black
line). Mice were weighed every four days until day 28 post-injection.
Data is presented as mean ± SD with n = 8 per group. (C) Biochemical
and hematological parameters assessed in C57BL/6 mice 28 days after
systemic administration of ZnPC-ITLs. Data is presented as mean ± SD
with n = 8 per group. Statistical analysis was performed as described in
section "Statistical analysis". Abbreviations: ALT, alanine transaminase;
AST, aspartate transaminase; CK-MB, creatine kinase M and B; CPK, creatine
phosphokinase; LDH, lactate dehydrogenase. (D) Histology of liver, spleen, and
lung of C57BL/6 mice 28 days after systemic administration of ZnPC-ITLs or
physiological buffer (control). Hematoxylin and eosin staining, magnification
20 × . (DOC 5788 kb)
Additional file 2: Figure S2. Validation of absolute log2 fold-changes
as obtained by microarray with qRT-PCR. Microarray-derived transcript
levels of a panel of genes are depicted for the ITL 50 and ITL 500 group
in white and green, respectively. The corresponding qRT-PCR levels of
these genes are depicted for the ITL 50 group in grey and the ITL 500
group in red. Gene expression is depicted as the log2 fold-change
between treated and untreated cells. The microarray and qRT-PCR data
were normalized to the expression level of the reference gene RPS18.
(DOC 247 kb)
Additional file 3: Table S1. Overview of transcriptional targets of the
five survival pathways. Official gene names are listed that were derived
from the Hugo Gene Nomenclature Committee (HGNC) along with their
Genbank accession numbers (Gene ID). (XLSX 16 kb)
Additional file 4: Figure S3. Analysis of qRT-PCR products by gel
electrophoresis. (A) Lane 1 contains a ladder and lanes 2 – 8 show the
specific qRT-PCR products of the genes that are listed on top of eachlane. (B) Lane 1 contains a ladder and lane 2 shows the reference gene
RPS18. The amplicon size of a specific gene product is noted in parentheses
below each gene name. (DOC 1796 kb)
Additional file 5: Table S2. Overview of primer sequences and
resulting amplicon sizes (in bp) that were used for the validation of
microarray expression levels using qRT-PCR. The primers are listed in the
5′ to 3′ direction. Primers were derived from RTPrimerDB (http://
www.rtprimerdb.org/), NCBI primer Blast (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/), and qPrimerDepot (http://primerdepot.nci.nih.gov/).
Sequencing of the qRT-PCR products, which were analyzed using NCBI
Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi), confirmed the correct
identity of each product. (XLSX 14 kb)
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